AMG National Trust Bank Makes New $5.84 Million Investment in CVS Health Corporation $CVS

Key Points

• AMG National Trust Bank initiated a $5.84 million position in CVS Health by purchasing 56,464 shares during the second quarter. Institutional investors collectively own 80.66% of the company.
• CVS Health reported quarterly EPS of $2.58, exceeding estimates of $1.87, while revenue rose 7.3% year over year to $106.1 billion. The company issued fiscal 2026 EPS guidance of $7.90–$8.10.
• Analysts maintain a favorable outlook, with 22 Buy ratings and two Holds, producing a consensus “Moderate Buy” rating and an average price target of $106.75. CVS also pays a quarterly dividend of $0.665, representing a 2.7% annualized yield.

AMG National Trust Bank bought a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 56,464 shares of the pharmacy operator's stock, valued at approximately $5,841,000.

Several other large investors also recently bought and sold shares of CVS. Simplicity Wealth LLC purchased a new stake in CVS Health in the second quarter valued at approximately $3,937,000. Wealth Effects LLC acquired a new position in CVS Health during the second quarter worth $664,000. Chase Investment Counsel Corp purchased a new position in shares of CVS Health during the second quarter worth $484,000. HBK Sorce Advisory LLC acquired a new stake in shares of CVS Health in the second quarter valued at $2,264,000. Finally, German American Bancorp Inc. acquired a new stake in shares of CVS Health during the second quarter worth about $419,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

Insiders Place Their Bets

In other news, Director Larry Robbins sold 370,462 shares of the firm's stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares of the company's stock, valued at $450,877,466.55. This trade represents a 7.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders sold 3,372,000 shares of company stock valued at $317,473,598. 0.85% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Argus lifted their price objective on shares of CVS Health from $90.00 to $104.00 and gave the company a "buy" rating in a report on Thursday, May 14th. Wall Street Zen raised shares of CVS Health from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Barclays boosted their price target on shares of CVS Health from $106.00 to $108.00 and gave the stock an "overweight" rating in a research note on Thursday, August 6th. Morgan Stanley increased their price objective on CVS Health from $106.00 to $111.00 and gave the company an "overweight" rating in a research note on Thursday, June 4th. Finally, Wells Fargo & Company lifted their target price on CVS Health from $103.00 to $123.00 and gave the company an "overweight" rating in a report on Monday, July 13th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $106.75.

CVS Health Stock Performance

Shares of CVS stock opened at $97.09 on Monday. The stock's 50-day moving average is $102.52 and its two-hundred day moving average is $88.26. The firm has a market cap of $124.18 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 0.93 and a beta of 0.61. CVS Health Corporation has a 1 year low of $67.42 and a 1 year high of $110.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $1.87 by $0.71. The business had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company's quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were given a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. CVS Health's dividend payout ratio (DPR) is presently 70.37%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source